A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Menlo Therapeutics
- 12 Feb 2019 Status changed from planning to recruiting.
- 08 Oct 2018 According to a Menlo Therapeutics media release, results from this study are expected in the first half of 2020.
- 08 Aug 2018 New trial record